Advertisement
Research Article Free access | 10.1172/JCI112826
Find articles by Papic, M. in: JCI | PubMed | Google Scholar
Find articles by Stein-Streilein, J. in: JCI | PubMed | Google Scholar
Find articles by Zakarija, M. in: JCI | PubMed | Google Scholar
Find articles by McKenzie, J. in: JCI | PubMed | Google Scholar
Find articles by Guffee, J. in: JCI | PubMed | Google Scholar
Find articles by Fletcher, M. in: JCI | PubMed | Google Scholar
Published February 1, 1987 - More info
Natural killer (NK) cells were assessed in patients with hyperthyroxinemia due to Graves' disease or treatment with thyroxine (T4). Cytolytic activity was measured with 51Cr-labeled K562 tumor cells and NK enumeration was by flow cytometry using NKH-1 monoclonal antibody to identify the relevant surface marker. Activity was uniformly decreased in association with hyperthyroxinemia, regardless of the underlying pathology; however, there was no reduction in the number of NKH-1+ cells. NK activity was enhanced by addition of interleukin 2 (IL-2) in both control and patients' cells although the value in the latter instance failed to reach the basal control level. Production of IL-2 by lymphocytes from hyperthyroxinemic subjects, in response to phytohemagglutinin, was also reduced. Since NK cells are thought to act as a defense against viral infections and some malignancies and may play a role in autoregulation of the immune system, this effect of T4 may have significant biological implications.